APA (7th ed.) Citation

Y, L., D, Z., C, X., KW, H., B, M., J, Q., . . . KM, L. (2018). Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Science translational medicine, 10(424), . https://doi.org/10.1126/scitranslmed.aan5488

Chicago Style (17th ed.) Citation

Y, Lan, et al. "Enhanced Preclinical Antitumor Activity of M7824, a Bifunctional Fusion Protein Simultaneously Targeting PD-L1 and TGF-β." Science Translational Medicine 10, no. 424 (2018). https://doi.org/10.1126/scitranslmed.aan5488.

MLA (9th ed.) Citation

Y, Lan, et al. "Enhanced Preclinical Antitumor Activity of M7824, a Bifunctional Fusion Protein Simultaneously Targeting PD-L1 and TGF-β." Science Translational Medicine, vol. 10, no. 424, 2018, https://doi.org/10.1126/scitranslmed.aan5488.